@LabRutella

Haematologist and Scientist

Joined May 2019
  • Tweets37
  • Following18
  • Followers47
2Media
lnkd.in/ddBSSpe
Rutella Lab retweeted
AML Hub
@AML_Hub10 Dec 2023
CONGRESS | #ASH23 | Sergio Rutella, @TrentUni shares data on W-NK, concluding that W-NK cells are effective against AML cells under culture conditions to mimic hypoxia and immunosuppressive TME. W-NK is also observed to persist in BM tissues, to control AML in vivo. #AMLsm #leusm
3
2
11
3,584
Immunogenomic landscape of p53 AML. Sergio Rutella, M.D., Ph.D., Nottingham University, UK. April 26th, Genomic Workshop &Hem Malig symposium. Georgetown MedStar Unv. hospital. Register eventbrite.com/e/genomics-wo…. @ASH_hematology @LombardiCancer @BCMCancerCenter @leukaemielabor – at Washington, DC

Genomics Workshop and 6th Annual Myeloid Malignancies Symposium

This event will provide a deep dive into the clinical application of genomics in myeloid and lymphoid neoplasms.

eventbrite.com
2
4
240
Farhad Ravandi, M.D., AML MRD optimization before BMT, MD Anderson CC. April 27th, 10:50 am. Goldberg auditorium, MGHU. Register: eventbrite.com/e/genomics-wo… @LombardiCancer @BCMCancerCenter @aamdsif @LLSusa @leukaemielabor @ASH_hematology @SocietyofHemOnc @HMHNewJersey – at Naples, Campania

Genomics Workshop and 6th Annual Myeloid Malignancies Symposium

This event will provide a deep dive into the clinical application of genomics in myeloid and lymphoid neoplasms.

eventbrite.com
3
3
350
#EBMT21 Leo Luznik on the results of the BMT CTN 1301 trial comparing calcineurin inhibitor-free GVHD prophylaxis in HCT recipients who received myeloablative conditioning & had HLA-matched donors #bmtsm (2/2)
5
14
#EBMT21 Leo Luznik on the results of the BMT CTN 1301 trial comparing calcineurin inhibitor-free GVHD prophylaxis in HCT recipients who received myeloablative conditioning & had HLA-matched donors #bmtsm (1/2)
1
21
2
34
Escape from T-cell targeting immunotherapies in acute myeloid leukemia ashpublications.org/blood/ar…

Escape from T-cell–targeting immunotherapies in acute myeloid leukemia

Introduced by Associate Editor Robert Zeiser, this Review Series focuses on the problem of immune escape by acute myeloid leukemia (AML). The series opens

ashpublications.org
2
4
221
Escape from T-cell targeting immunotherapies in acute myeloid leukemia ashpublications.org/blood/ar…

Escape from T-cell–targeting immunotherapies in acute myeloid leukemia

Introduced by Associate Editor Robert Zeiser, this Review Series focuses on the problem of immune escape by acute myeloid leukemia (AML). The series opens

ashpublications.org
119
Check this out! Closing date: 30th June 2023. lnkd.in/eTczg3-a

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
77
Open PhD position in my lab. Check it out! #phdstudent #phd #immunooncology #immunotherapy #ash_hematology #cancerresearch lnkd.in/eWxBWaGf

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
1
221
I am hiring! Just reach out to discuss, if you think you have the right skills and expertise. #hiring #ash_hematology #immunology #immunotherapy lnkd.in/dtnkaAhn

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
4
4
772
Great to see very broad coverage of our AML work and an Altmetric score of 1,174! #ash_hematology #ash22 #immunotherapy #immunooncology #nottinghamtrentuniversity lnkd.in/d7U8mHZr

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
1
4
#bsh_haematology #ash_hematology #ash22 lnkd.in/eA9GjmNH

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
3
Fighting aggressive blood cancer ages and exhausts immune cells, study suggests independent.co.uk/news/uk/pa…

Fighting aggressive blood cancer ages and exhausts immune cells, study suggests

Patients with highly exhausted immune cells had been less likely to respond to immunotherapy than other patients, the researchers found.

independent.co.uk
1
3
Our T-cell dysfunction/senescence paper is finally out! #ASH22 @ash_hematology lnkd.in/d5SCUCeC

LinkedIn

This link will take you to a page that’s not on LinkedIn

lnkd.in
2
2
Signatures of immune dysfunction predict outcomes and define checkpoint blockade-unresponsive microenvironments in … pubmed.ncbi.nlm.nih.gov/3609…

Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microe...

BackgroundImmune exhaustion and senescence are dominant dysfunctional states of effector T cells and major hurdles for the success of cancer immunotherapy. In the current study, we characterized how...

pubmed.ncbi.nlm.nih.gov
1
ESMO Congress 2022: LIVE Plus Prof. Solange Peters, ESMO President 2020-... youtu.be/ARQyVS-hR4c via @YouTube
Why the party is over for Britain’s Research Excellence Framework nature.com/articles/d41586-0…
Research Fellow - Nottingham Trent University vacancies.ntu.ac.uk/displayj…
1
Signatures of immune senescence predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia medrxiv.org/content/10.1101/…

Signatures of immune senescence predict outcomes and define checkpoint blockade-unresponsive...

The function of senescent-like T cells, transcriptomic features of immune effector senescence (IES) and their influence on therapeutic response were investigated in independent AML clinical cohorts...

medrxiv.org
1
3
#ESMOImmuno21: Your chance to help us shape the future of immuno-oncology. Watch Kevin Harrington explain why you can’t miss this event and register to participate online. 👉 ow.ly/BxBF50GXhe7 #immunooncology #immunotherapy #cancerresearch #immunonc
5
1
11
Load more